Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Profitability
This table compares Cellectar Biosciences and Green Thumb Industries’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectar Biosciences | N/A | -349.24% | -153.18% |
| Green Thumb Industries | 10.14% | 5.79% | 3.98% |
Volatility & Risk
Cellectar Biosciences has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Green Thumb Industries has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectar Biosciences | 1 | 0 | 3 | 0 | 2.50 |
| Green Thumb Industries | 0 | 1 | 1 | 1 | 3.00 |
Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 243.75%. Given Cellectar Biosciences’ higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Green Thumb Industries.
Insider and Institutional Ownership
16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 0.1% of Green Thumb Industries shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by insiders. Comparatively, 9.4% of Green Thumb Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Cellectar Biosciences and Green Thumb Industries”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectar Biosciences | N/A | N/A | -$21.79 million | ($6.66) | -0.48 |
| Green Thumb Industries | $1.18 billion | 1.26 | $114.15 million | $0.51 | 14.00 |
Green Thumb Industries has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Green Thumb Industries, indicating that it is currently the more affordable of the two stocks.
Summary
Green Thumb Industries beats Cellectar Biosciences on 11 of the 14 factors compared between the two stocks.
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
About Green Thumb Industries
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
